Evaluation of Immune Response Elicited by Inulin as an Adjuvant with Filarial Antigens in Mice Model

Scandinavian Journal of Immunology

Volumn 80, Issue 4, 2014, Pages 261-270

  Mahalakshmi, N ^a   Aparnaa, R ^a   Kaliraj, P ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOLOGICAL ADJUVANT; INDUCIBLE NITRIC OXIDE SYNTHASE; INULIN; NITRIC OXIDE; SECRETED LARVAL ACIDIC PROTEIN 1; UNCLASSIFIED DRUG; VENOM ALLERGEN HOMOLOGUE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; HELMINTH ANTIBODY; HELMINTH PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; PARASITE ANTIGEN; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BRUGIA MALAYI; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; FILARIASIS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; ONCHOCERCA VOLVULUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; IMMUNOLOGY; MALE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; BRUGIA MALAYI; DISEASE MODELS, ANIMAL; FILARIASIS; HELMINTH PROTEINS; IMMUNOGLOBULIN G; INULIN; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE TYPE II; ONCHOCERCA VOLVULUS; PROTOZOAN VACCINES; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; VACCINATION;

EID: 84927565142     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12208     Document Type: Article

References (47)

1. World Health Organization. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 2006;22:221-32.
2. Veerapathran A, Dakshinamoorthy G, Gnanasekar M, Reddy MVR, Kalyanasundaram R. Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Negl Trop Dis 2009;3:e457.
3. Fan PC. Diethylcarbamazine treatment of bancroftian and Malayan filariasis with emphasis on side effects. Ann Trop Med Parasitol 1992;86:399-405.
4. Lizotte-Waniewski M, Tawe W, Guiliano DB et al. Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries. Infect Immun 2000;68:3491-501.
5. Gregory WF, Atmadja AK, Allen JE, Maizels RM. The abundant larval transcript-1 and -2 genes of Brugia malayi encode stage-specific candidate vaccine antigens for filariasis. Infect Immun 2000;68:4174-9.
6. Graham SP, Lustigman S, Trees AJ, Bianco AE. O. volvulus: comparative analysis of antibody responses to recombinant antigens in two animal models of onchocerciasis. Exp Parasitol 2000;94:158-62.
7. Wu Y, Egerton G, Pappin JCD et al. The secreted larval acidic proteins (SLAPs) of Onchocerca spp. are encoded by orthologues of the alt gene family of Brugia malayi and have host protective potential. Mol Biochem Parasitol 2000;134:213-24.
8. Thirugnanam S, Pandiaraja P, Ramaswamy K et al. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2-DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model. Exp Parasitol 2007;116:483-91.
9. Anand SB, Kodumudi KN, Reddy MVR, Kaliraj P. A combination of two Brugia malayi filarial vaccine candidate antigens (BmALT-2 and BmVAH) enhances immune responses and protection in jirds. J Helminthol 2011;85:442-52.
10. Sharmila S, Christiana I, Kiran P, Reddy MVR, Sankaran K, Kaliraj P. Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model. Parasite Immunol 2013;35:201-13.
11. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 2008;7:7-10.
12. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009;9:287-93.
13. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993;14:281-4.
14. Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993;11:914-8.
15. Hernandez I, Sanmartin O, Carda C, Gome S, Alfaro A. B-cell pseudolymphoma caused by aluminium hydroxide following hyposensitization therapy. Actas Dermosifiliogr 2008;99:213-6.
16. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999;55:1878-84.
17. Cooper PD, McComb C, Steele EJ. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 1991;9:408-15.
18. Cooper PD. Vaccine adjuvants based on gamma inulin. Pharm Biotechnol 1995;6:559-80.
19. Cooper PD, Carter M. Anticomplementary action of polymorphic solubility forms of particulate inulin. Mol Immunol 1986;23:895-901.
20. Klaus GGN, Humphery JH. A re-evaluation of the role of C3 in B cell activation. Immunol Today 1986;7:163-5.
21. Anand SB, Murugan V, Prabhu PR, Anandharaman V, Reddy MVR, Kaliraj P. Comparison of immunogenicity, protective efficacy of single and cocktail DNA vaccine of Brugia malayi abundant larval transcript (ALT-2) and thioredoxin peroxidase (TPX) in mice. Acta Trop 2008;107:106-12.
22. Chandrashekar R, Rao UR, Subramanyam D. Antibody mediated cytotoxicity effects in vitro and in vivo of rat cells on infective larvae of Brugia malayi. Int J Parasitol 1990;20:725-30.
23. Rizzo LV, DeKruyff RH, Umetsu DT. Generation of B cell memory and affinity maturation: induction of Th1 and Th2 cell clones. J Immunol 1992;148:3733-9.
24. Rajan TV, Porte P, Yates JA, Keefer L, Shultz LD. Role of nitric oxide in host defense against an extracellular metazoan parasite, Brugia malayi. Infect Immun 1996;64:3351-3.
25. Taylor MJ, Cross HF, Mohammed AA, Trees AJ, Binaco AE. Susceptibility of Brugia malayi and Onchocerca lienalis microfilariae to nitric oxide and hydrogen peroxide in cell-free culture and from IFN-γ activated macrophages. Parasitology 1996;112:315-22.
26. Chandrashekar R, Rao UR, Subrahmanyam D. Serum dependent cell-mediated immune reactions to Brugia pahangi infective larvae. Parasite Immunol 1985;7:633-41.
27. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
28. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 1999;29:924-7.
29. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse of multiple sclerosis. N Engl J Med 2001;344:319-26.
30. Anand SB, Gnanasekar M, Thangadurai M, Prince PR, Kaliraj P, Ramaswamy K. Immune response studies with Wuchereria boncrofti vespid allergen homologue (WbVAH) in human lymphatic filariasis. Parasitol Res 2007;101:981-8.
31. Gotze O, Muller-Eberhard HJ. The C3-activator system: an alternative pathway of complement activation. J Exp Med 1971;134:90s-108s.
32. Kerekes K, Cooper PD, Prechl J, Józsi M, Bajtay Z, Erdei Al. Adjuvant effect of gamma-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J Leukoc Biol 2001;69:69-74.
33. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488-96.
34. Lawrence RA. Immunity to filarial nematodes. Vet Parasitol 2001;100:33-44.
35. Rotman HL, Daly TM, Clynes R, Long CA. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J Immunol 1998;161:1908-12.
36. Jin BR, Kim SJ, Lee JM et al. Alum directly modulates murine B lymphocytes to produce IgG1 isotype. Immune Netw 2013;13:10-5.
37. Shenoy AM, Brahmi Z. Human IgG1 and mouse IgG3 but not monomeric IgM or IgE facilitate antibody-dependent cell-mediated cytotoxicity by human natural killer cells. Nat Immun Cell Growth Regul 1989;8:338-48.
38. Sim BK, Kwa BH, Mak JW. Immune responses in human Brugia malayi infections: serum dependent cell mediated destruction of infective larvae in vitro. Trans R Soc Trop Med Hyg 1982;76:362-9.
39. Lobigs M, Pavy M, Hall RA et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010;91:1407-17.
40. Le Goff L, Loke P, Ali HF, Taylor DW, Allen JE. Interleukin-5 is essential for vaccine-mediated immunity buy not innate resistance to a filarial parasite. Infect Immun 2000;68:2513-7.
41. Al-Qaoud KM, Pearlman E, Hartung T, Klukowski J, Fleischer B, Hoeruf A. A new mechanism for IL-5 dependent helminth control: neutrophil accumulation and neutrophil-mediated worm encapsulation in murine filariasis are abolished in the absence of IL-5. Int Immunol 2000;12:899-908.
42. Gu Y, Kuida K, Tsutsui H et al. Activation of interferon-gamma inducing factor mediated by interleukin-1 beta converting enzyme. Science 1997;275:206-9.
43. Liew FY, Wei X, Proudfoot L. Cytokines and nitric oxide as effector molecule against parasitic infections. Philos Trans R Soc Lond B Biol Sci 1997;352:1311-5.
44. Lange AM, Yutanawiboonchai W, Scott P, Abraham D. IL-4 and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice. J Immunol 1994;153:205-11.
45. Arimoto T, Choi DY, Lu X et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging 2007;28:894-906.
46. Madhumathi J, Prince PR, Anugraha G et al. Identification of nematode specific protective epitopes of B. malayi TRX towards development of synthetic vaccine construct for lymphatic filariasis. Vaccine 2010;28:5038-48.
47. MacDonald AJ, Cao L, He Y, Zhao Q, Jiang S, Lustigman S. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypetide and SARS-CoV peptide antigens. Vaccine 2005;23:3446-52.